Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Jaskaran Singh's publication output changed over time?
ScholarIQpublication output · 2006–2020
Output declined50% over the shown period — from 2 works in 2006 to 1 in 2020.
2
1
1
1
1
4
1
2006201520162017201820192020
What are the most-cited papers on Jaskaran Singh?
ScholarIQmost cited works
A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression
Carlos A. Zarate, Jaskaran Singh, Paul J. Carlson, Nancy E. Brutsché, Rezvan Ameli, David A. Luckenbaugh, Dennis S. Charney, Husseini K. Manji
S126359496. 20063,782 CitationsOPEN ACCESS
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study
Vanina Popova, Ella Daly, Madhukar H. Trivedi, Kimberly Cooper, Rosanne Lane, Pilar Lim, Christine Mazzucco, David Hough, Michael E. Thase, Richard C. Shelton, Patricio Molero, Eduard Vieta, Malek Bajbouj, Husseini K. Manji, Wayne C. Drevets, Jaskaran Singh
S116025658. 2019886 CitationsOPEN ACCESS
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression
Ella Daly, Madhukar H. Trivedi, Adam Janik, Honglan Li, Yun Zhang, Xiang Li, Rosanne Lane, Pilar Lim, A. Duca, David Hough, Michael E. Thase, John Zajecka, Andrew Winokur, Ilona Divacka, Andrea Fagiolini, Wiesław Jerzy Cubała, István Bitter, Pierre Blier, Richard C. Shelton, Patricio Molero, Husseini K. Manji, Wayne C. Drevets, Jaskaran Singh
S2495708506. 2019779 CitationsOPEN ACCESS
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression
Ella Daly, Jaskaran Singh, Maggie Fedgchin, Kimberly Cooper, Pilar Lim, Richard C. Shelton, Michael E. Thase, Andrew Winokur, Luc Van Nueten, Husseini K. Manji, Wayne C. Drevets
S2495708506. 2017712 CitationsOPEN ACCESS
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study
Carla M. Canuso, Jaskaran Singh, Maggie Fedgchin, Larry Alphs, Rosanne Lane, Pilar Lim, Christine Pinter, David Hough, Gerard Sanacora, Husseini K. Manji, Wayne C. Drevets
S116025658. 2018669 CitationsOPEN ACCESS
Related on ScholarIQ
Neurocrine Biosciences (United States)
Institution
A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression
Paper
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study
Paper
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression
Paper
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression
Paper
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study
Paper